JP2016520320A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520320A5 JP2016520320A5 JP2016516173A JP2016516173A JP2016520320A5 JP 2016520320 A5 JP2016520320 A5 JP 2016520320A5 JP 2016516173 A JP2016516173 A JP 2016516173A JP 2016516173 A JP2016516173 A JP 2016516173A JP 2016520320 A5 JP2016520320 A5 JP 2016520320A5
- Authority
- JP
- Japan
- Prior art keywords
- activity
- cell
- variant
- seq
- onui
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 claims description 24
- 102100031780 Endonuclease Human genes 0.000 claims description 23
- 108010042407 Endonucleases Proteins 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 108020004414 DNA Proteins 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical group 0.000 claims description 8
- 108020001580 protein domains Proteins 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 claims description 6
- 230000003197 catalytic effect Effects 0.000 claims description 6
- 108091007494 Nucleic acid- binding domains Proteins 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 108060002716 Exonuclease Proteins 0.000 claims description 4
- 101000830950 Homo sapiens Three prime repair exonuclease 2 Proteins 0.000 claims description 4
- 102100024872 Three prime repair exonuclease 2 Human genes 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 102000013165 exonuclease Human genes 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 2
- 101000634853 Homo sapiens T cell receptor alpha chain constant Proteins 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 claims description 2
- 108010061833 Integrases Proteins 0.000 claims description 2
- 102000003960 Ligases Human genes 0.000 claims description 2
- 108090000364 Ligases Proteins 0.000 claims description 2
- 108060004795 Methyltransferase Proteins 0.000 claims description 2
- 101100508818 Mus musculus Inpp5k gene Proteins 0.000 claims description 2
- 101710163270 Nuclease Proteins 0.000 claims description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 101100366438 Rattus norvegicus Sphkap gene Proteins 0.000 claims description 2
- 102000018120 Recombinases Human genes 0.000 claims description 2
- 108010091086 Recombinases Proteins 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 101710183280 Topoisomerase Proteins 0.000 claims description 2
- 108700019146 Transgenes Proteins 0.000 claims description 2
- 102000008579 Transposases Human genes 0.000 claims description 2
- 108010020764 Transposases Proteins 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 102000034287 fluorescent proteins Human genes 0.000 claims description 2
- 108091006047 fluorescent proteins Proteins 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 238000002703 mutagenesis Methods 0.000 claims description 2
- 231100000350 mutagenesis Toxicity 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 230000019491 signal transduction Effects 0.000 claims 2
- 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201370303 | 2013-05-31 | ||
| DKPA201370303 | 2013-05-31 | ||
| PCT/EP2014/061189 WO2014191527A1 (en) | 2013-05-31 | 2014-05-28 | A laglidadg homing endonuclease cleaving the t cell receptor alpha gene and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520320A JP2016520320A (ja) | 2016-07-14 |
| JP2016520320A5 true JP2016520320A5 (enExample) | 2017-07-06 |
| JP6450371B2 JP6450371B2 (ja) | 2019-01-09 |
Family
ID=48628226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516173A Active JP6450371B2 (ja) | 2013-05-31 | 2014-05-28 | Ｔ細胞受容体α遺伝子を開裂するＬＡＧＬＩＤＡＤＧホーミングエンドヌクレアーゼおよびその用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10000746B2 (enExample) |
| EP (1) | EP3004338B1 (enExample) |
| JP (1) | JP6450371B2 (enExample) |
| AU (1) | AU2014273091B2 (enExample) |
| CA (1) | CA2913872C (enExample) |
| DK (1) | DK3004338T3 (enExample) |
| ES (1) | ES2716867T3 (enExample) |
| WO (1) | WO2014191527A1 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201602651YA (en) * | 2011-04-05 | 2016-05-30 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| ES2670983T3 (es) | 2013-11-07 | 2018-06-04 | Editas Medicine, Inc. | Métodos y composiciones relacionados con CRISPR con ARNg rectores |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| EP3680329B1 (en) * | 2015-10-05 | 2021-06-09 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| AU2016333898B2 (en) | 2015-10-05 | 2020-11-12 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene |
| IL294014B2 (en) | 2015-10-23 | 2024-07-01 | Harvard College | Nucleobase editors and uses thereof |
| CA3006432A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| SG11201807820PA (en) * | 2016-03-11 | 2018-10-30 | Bluebird Bio Inc | Genome edited immune effector cells |
| KR20240144489A (ko) * | 2016-04-14 | 2024-10-02 | 프레드 허친슨 캔서 센터 | 표적화 핵산 나노수송체를 이용하여 치료 세포를 프로그램화하기 위한 조성물 및 방법 |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| EP3487994A4 (en) * | 2016-07-25 | 2020-01-29 | Bluebird Bio, Inc. | HOMING BCL11A ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
| MA45996A (fr) * | 2016-08-16 | 2021-06-02 | Bluebird Bio Inc | Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées |
| EP3504335A4 (en) * | 2016-08-23 | 2020-04-15 | Bluebird Bio, Inc. | HOMING TIM3 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR102622910B1 (ko) | 2016-09-08 | 2024-01-10 | 2세븐티 바이오, 인코포레이티드 | Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법 |
| WO2018071565A1 (en) * | 2016-10-11 | 2018-04-19 | Bluebird Bio, Inc. | TCRa HOMING ENDONUCLEASE VARIANTS |
| CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
| CA3040157A1 (en) | 2016-10-17 | 2018-04-26 | Bluebird Bio, Inc. | Tgf.beta.r2 endonuclease variants, compositions, and methods of use |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| CA3049244A1 (en) | 2017-01-05 | 2018-07-12 | Fred Hutchinson Cancer Research Center | Systems and methods to improve vaccine efficacy |
| WO2018165631A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Cancer vaccine |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| SG11201907434RA (en) | 2017-03-22 | 2019-10-30 | Novartis Ag | Compositions and methods for immunooncology |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| CA3059643A1 (en) | 2017-04-13 | 2018-10-18 | Cellectis | New sequence specific reagents targeting ccr5 in primary hematopoietic cells |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| IL313037A (en) * | 2017-05-25 | 2024-07-01 | 2Seventy Bio Inc | Cblb endonuclease variants, compositions, and methods of use |
| US11053484B2 (en) | 2017-06-30 | 2021-07-06 | Precision Biosciences, Inc. | Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| US11779654B2 (en) * | 2017-10-04 | 2023-10-10 | 2Seventy Bio, Inc. | PCSK9 endonuclease variants, compositions, and methods of use |
| JP7333495B2 (ja) | 2017-10-10 | 2023-08-25 | 国立大学法人広島大学 | エフェクターＴ細胞（Ｔｅｆｆ）抗原受容体を用いた抗原特異的制御性Ｔ細胞（Ｔｒｅｇ）の作出技術 |
| EP3702453A4 (en) * | 2017-10-10 | 2021-07-21 | Hiroshima University | TOTAL REPLACEMENT TECHNIQUE FOR T-LYMPHOCYTE RECEPTOR USING PLATINUM TALENE |
| CN111757937A (zh) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | 腺苷碱基编辑器的用途 |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US20210002621A1 (en) * | 2017-12-20 | 2021-01-07 | Bluebird Bio, Inc. | Ctla4 homing endonuclease variants, compositions, and methods of use |
| IL317539A (en) | 2018-04-12 | 2025-02-01 | Prec Biosciences Inc | Optimized engineered nucleases with specificity for the human T-cell receptor alpha constant region gene |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2019241685A1 (en) | 2018-06-14 | 2019-12-19 | Bluebird Bio, Inc. | Cd79a chimeric antigen receptors |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| EP3893922A4 (en) | 2018-12-10 | 2022-09-14 | 2seventy bio, Inc. | VARIANTS OF ENDONUCLEASE HOMING |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CA3130488A1 (en) | 2019-03-19 | 2020-09-24 | David R. Liu | Methods and compositions for editing nucleotide sequences |
| MX2021012110A (es) | 2019-04-03 | 2022-01-06 | Prec Biosciences Inc | Celulas inmunitarias geneticamente modificadas que comprenden un arnhc adaptado a microarn (arnhcmir). |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| EP4004216A1 (en) | 2019-07-25 | 2022-06-01 | Precision BioSciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
| AU2020333851A1 (en) | 2019-08-20 | 2022-03-31 | Precision Biosciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US20220411479A1 (en) | 2019-10-30 | 2022-12-29 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| EP4192875A1 (en) | 2020-08-10 | 2023-06-14 | Precision BioSciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
| WO2022140150A1 (en) * | 2020-12-21 | 2022-06-30 | 2Seventy Bio, Inc. | Compositions and methods for site-directed mutagenesis |
| EP4284823A1 (en) | 2021-01-28 | 2023-12-06 | Precision BioSciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| EP4426832A1 (en) | 2021-11-03 | 2024-09-11 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Precise genome editing using retrons |
| WO2023081767A1 (en) | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
| AU2022395500A1 (en) | 2021-11-23 | 2024-05-23 | Cellectis Sa | New tale protein scaffolds with improved on-target/off-target activity ratios |
| WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| EP4646223A1 (en) | 2023-01-05 | 2025-11-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| US20140148361A1 (en) * | 2010-06-07 | 2014-05-29 | Barry L. Stoddard | Generation and Expression of Engineered I-ONUI Endonuclease and Its Homologues and Uses Thereof |
| SG10201602651YA (en) * | 2011-04-05 | 2016-05-30 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| EP2729567B1 (en) * | 2011-07-08 | 2016-10-05 | Cellectis | Method for increasing the efficiency of double-strand break-induced mutagenssis |
| WO2013068845A2 (en) * | 2011-11-07 | 2013-05-16 | The University Of Western Ontario | Endonuclease for genome editing |
-
2014
- 2014-05-28 DK DK14728899.7T patent/DK3004338T3/en active
- 2014-05-28 EP EP14728899.7A patent/EP3004338B1/en active Active
- 2014-05-28 ES ES14728899T patent/ES2716867T3/es active Active
- 2014-05-28 WO PCT/EP2014/061189 patent/WO2014191527A1/en not_active Ceased
- 2014-05-28 US US14/891,216 patent/US10000746B2/en active Active
- 2014-05-28 JP JP2016516173A patent/JP6450371B2/ja active Active
- 2014-05-28 CA CA2913872A patent/CA2913872C/en active Active
- 2014-05-28 AU AU2014273091A patent/AU2014273091B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520320A5 (enExample) | ||
| JP2016520319A5 (enExample) | ||
| JP7553110B2 (ja) | エピゲノム編集のための組成物および方法 | |
| KR102796744B1 (ko) | 이식의 개선을 위한 crispr/cas-관련 방법 및 조성물 | |
| JP2023078373A (ja) | Ｒｎａを編集する方法および組成物 | |
| JP2025065213A (ja) | 免疫療法のための改変ナチュラルキラー（ｎｋ）細胞 | |
| JP2017018125A5 (enExample) | ||
| JP2023002785A (ja) | 変異ｃａｓ９タンパク質 | |
| WO2013186563A3 (en) | Factor viii sequences | |
| JP2015533786A5 (enExample) | ||
| WO2017011773A3 (en) | Codon-optimized nucleic acids encoding antibodies | |
| JP2020530437A5 (enExample) | ||
| FI3352776T3 (fi) | Htt-repressoreita ja niiden käyttötapoja | |
| JP2015503535A5 (enExample) | ||
| JP2017513472A5 (enExample) | ||
| US12297426B2 (en) | DNA damage response signature guided rational design of CRISPR-based systems and therapies | |
| US11072782B2 (en) | Construct for epigenetic modification and its use in the silencing of genes | |
| CA3191148A1 (en) | Engineered immune cells with priming receptors | |
| EA201070108A1 (ru) | Cd44 сплайс-варианты в нейродегенеративных заболеваниях | |
| AU2021369494A1 (en) | Safe harbor loci | |
| KR20250134148A (ko) | Scn9a 또는 scn10a 유전자를 변형시키기 위한 유전자-편집 시스템 및 이의 방법 및 용도 | |
| WO2016086768A1 (zh) | 特异识别并修复β地中海贫血症beta-globin基因的嵌合核酸酶 | |
| US20240287609A1 (en) | Compositions and methods for large-scale in vivo genetic screening | |
| Suresh | CRISPR-Cas9 Based Correction of a Pathogenic Microduplication and Engineering Artificial Transcription Factors for Gene Activation: Applications in Genome Engineering | |
| EA050294B1 (ru) | Безопасный локус |